JP2013535422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535422A5 JP2013535422A5 JP2013518498A JP2013518498A JP2013535422A5 JP 2013535422 A5 JP2013535422 A5 JP 2013535422A5 JP 2013518498 A JP2013518498 A JP 2013518498A JP 2013518498 A JP2013518498 A JP 2013518498A JP 2013535422 A5 JP2013535422 A5 JP 2013535422A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition
- posaconazole
- composition according
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 9
- 229960001589 posaconazole Drugs 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 7
- 238000001802 infusion Methods 0.000 claims 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 2
- 241000222122 Candida albicans Species 0.000 claims 2
- 206010007134 Candida infections Diseases 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 206010030154 Oesophageal candidiasis Diseases 0.000 claims 2
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 201000003984 candidiasis Diseases 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000005655 esophageal candidiasis Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims 1
- 108010049047 Echinocandins Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010061418 Zygomycosis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000024340 acute graft versus host disease Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims 1
- 229960003749 ciclopirox Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims 1
- 229960002867 griseofulvin Drugs 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000011368 intensive chemotherapy Methods 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 201000009085 invasive aspergillosis Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000007524 mucormycosis Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 206010052366 systemic mycosis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960002703 undecylenic acid Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35970110P | 2010-06-29 | 2010-06-29 | |
| US61/359,701 | 2010-06-29 | ||
| PCT/US2011/041715 WO2012005973A1 (en) | 2010-06-29 | 2011-06-24 | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535422A JP2013535422A (ja) | 2013-09-12 |
| JP2013535422A5 true JP2013535422A5 (https=) | 2014-07-17 |
| JP6008849B2 JP6008849B2 (ja) | 2016-10-19 |
Family
ID=45441500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518498A Active JP6008849B2 (ja) | 2010-06-29 | 2011-06-24 | 置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9023790B2 (https=) |
| EP (3) | EP3960185A1 (https=) |
| JP (1) | JP6008849B2 (https=) |
| KR (1) | KR101834024B1 (https=) |
| CN (2) | CN102958528A (https=) |
| AU (1) | AU2011276680B2 (https=) |
| BR (1) | BR112012033077B8 (https=) |
| CA (1) | CA2802929C (https=) |
| CY (1) | CY1124690T1 (https=) |
| DK (1) | DK3391890T3 (https=) |
| ES (1) | ES2893444T3 (https=) |
| HR (1) | HRP20211686T1 (https=) |
| HU (1) | HUE056581T2 (https=) |
| LT (1) | LT3391890T (https=) |
| MX (2) | MX338685B (https=) |
| PL (1) | PL3391890T3 (https=) |
| PT (1) | PT3391890T (https=) |
| RS (1) | RS62583B1 (https=) |
| SI (1) | SI3391890T1 (https=) |
| WO (1) | WO2012005973A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| MX338685B (es) | 2010-06-29 | 2016-04-26 | Merck Sharp & Dohme | Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida. |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| AU2014329421B2 (en) | 2013-10-03 | 2018-08-02 | Dow Pharmaceutical Sciences, Inc. | Stabilized efinaconazole compositions |
| CN104546724A (zh) * | 2013-10-12 | 2015-04-29 | 博瑞生物医药技术(苏州)有限公司 | 一种抗真菌药的固体分散体 |
| JP6611014B2 (ja) | 2013-11-22 | 2019-11-27 | ボシュ ヘルス アイルランド リミテッド | 抗感染方法、抗感染組成物、および抗感染装置 |
| CN105879041A (zh) * | 2014-11-14 | 2016-08-24 | 北京赛林泰医药技术有限公司 | 一种泊沙康唑口服液及其制备方法 |
| EA201791100A1 (ru) * | 2014-11-19 | 2017-11-30 | Гуфик Байосайенсиз Лимитед | Способ получения парентерального состава на основе анидулафунгина |
| CN104473871B (zh) * | 2014-11-28 | 2017-03-08 | 济南康和医药科技有限公司 | 一种泊沙康唑脂肪乳注射液及其制备方法 |
| CN106265534A (zh) * | 2015-05-25 | 2017-01-04 | 江苏正大丰海制药有限公司 | 一种泊沙康唑冻干粉针剂的制备方法 |
| CN106511262A (zh) * | 2015-09-11 | 2017-03-22 | 上海美悦生物科技发展有限公司 | 一种泊沙康唑口服溶液剂及其制备方法 |
| WO2017133632A1 (zh) | 2016-02-04 | 2017-08-10 | 武汉朗来科技发展有限公司 | 泊沙康唑衍生物、其药物组合物和用途 |
| CN110022857A (zh) | 2016-11-18 | 2019-07-16 | 艾库里斯抗感染治疗有限公司 | 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途 |
| WO2019201904A1 (en) | 2018-04-16 | 2019-10-24 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| CN110711174A (zh) * | 2018-07-11 | 2020-01-21 | 郑州泰丰制药有限公司 | 一种泊沙康唑注射液中间体溶液配制方法 |
| WO2020139209A1 (en) * | 2018-12-28 | 2020-07-02 | Polifarma Ilac Sanayi Ve Ticaret Anonim Srketi | Stable injectable posaconazole formulations comprising cyclodextrin and sugar |
| EP4161515A4 (en) * | 2020-06-06 | 2024-08-07 | Invengene Limited | STABLE LIQUID COMPOSITIONS OF POSACONAZOLE |
| CN115429748A (zh) * | 2021-06-02 | 2022-12-06 | 江苏奥赛康药业有限公司 | 一种泊沙康唑注射液的制备方法 |
| WO2023148763A1 (en) * | 2022-02-01 | 2023-08-10 | Cipla Limited | Injectable pharmaceutical compositions of azole antifungal agents |
| CN117783387A (zh) * | 2023-12-28 | 2024-03-29 | 郑州泰丰制药有限公司 | 一种测定泊沙康唑注射液包合常数的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5257985A (en) | 1989-12-04 | 1993-11-02 | Richard Puhl | Multi-chamber intravenous bag apparatus |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5661151A (en) | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| US5703079A (en) | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| IL112081A (en) | 1993-12-21 | 2001-08-26 | Schering Plough Corp | Tetrahydrofuran derivatives, their preparation and antifungal pharmaceutical compositions containing them |
| US5834472A (en) | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5972381A (en) | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| US6713481B1 (en) | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| US20030099674A1 (en) | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
| DE60330552D1 (de) | 2002-04-30 | 2010-01-28 | Otsuka Pharma Co Ltd | Medizinischer mehrkammerbehälter und beutel zu seiner umhüllung |
| EP1632228A4 (en) * | 2003-06-06 | 2006-11-29 | Sankyo Co | MEDICINAL COMPOSITION CONTAINING TRIAZOLE COMPOUND |
| CN1988887A (zh) * | 2004-05-28 | 2007-06-27 | 先灵公司 | 包含泊沙康唑的注射用药物混悬剂 |
| US20060160823A1 (en) | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
| JP4792032B2 (ja) * | 2004-08-13 | 2011-10-12 | シェーリング−プラウ・リミテッド | 抗生物質、トリアゾールおよびコルチコステロイドを含む薬学的処方物 |
| WO2006098345A1 (ja) * | 2005-03-15 | 2006-09-21 | Ajinomoto Co., Inc. | 薬剤移送具 |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| CN101370453B (zh) * | 2005-12-14 | 2013-12-18 | 努沃研究公司 | 用于皮肤输送药物的组合物和方法 |
| SG170047A1 (en) * | 2006-05-30 | 2011-04-29 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations |
| EP2061458B1 (en) * | 2006-09-15 | 2014-12-10 | Regents of the University of Minnesota | Topiramate compositions and methods for their use |
| JP2010515762A (ja) | 2007-01-16 | 2010-05-13 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポサコナゾール−ポリマー複合体、並びに、ポサコナゾールおよびそのポリマー複合体を使用した治療方法 |
| WO2009018069A2 (en) | 2007-07-30 | 2009-02-05 | Cydex Pharmaceuticals, Inc | Mixtures of cyclodextrin derivatives |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| JP2011529072A (ja) * | 2008-07-24 | 2011-12-01 | セラヴァンス， インコーポレーテッド | 二重作用血圧降下薬 |
| MX338685B (es) | 2010-06-29 | 2016-04-26 | Merck Sharp & Dohme | Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida. |
-
2011
- 2011-06-24 MX MX2012015168A patent/MX338685B/es active IP Right Grant
- 2011-06-24 JP JP2013518498A patent/JP6008849B2/ja active Active
- 2011-06-24 LT LTEP18171672.1T patent/LT3391890T/lt unknown
- 2011-06-24 WO PCT/US2011/041715 patent/WO2012005973A1/en not_active Ceased
- 2011-06-24 EP EP21192006.1A patent/EP3960185A1/en active Pending
- 2011-06-24 PL PL18171672T patent/PL3391890T3/pl unknown
- 2011-06-24 BR BR112012033077A patent/BR112012033077B8/pt not_active IP Right Cessation
- 2011-06-24 RS RS20211325A patent/RS62583B1/sr unknown
- 2011-06-24 DK DK18171672.1T patent/DK3391890T3/da active
- 2011-06-24 ES ES18171672T patent/ES2893444T3/es active Active
- 2011-06-24 US US13/704,145 patent/US9023790B2/en active Active
- 2011-06-24 SI SI201132006T patent/SI3391890T1/sl unknown
- 2011-06-24 CN CN2011800314889A patent/CN102958528A/zh active Pending
- 2011-06-24 PT PT181716721T patent/PT3391890T/pt unknown
- 2011-06-24 EP EP18171672.1A patent/EP3391890B1/en active Active
- 2011-06-24 AU AU2011276680A patent/AU2011276680B2/en active Active
- 2011-06-24 EP EP11804061.7A patent/EP2588116A4/en not_active Withdrawn
- 2011-06-24 CN CN201710169203.7A patent/CN107049935A/zh active Pending
- 2011-06-24 HR HRP20211686TT patent/HRP20211686T1/hr unknown
- 2011-06-24 CA CA2802929A patent/CA2802929C/en active Active
- 2011-06-24 HU HUE18171672A patent/HUE056581T2/hu unknown
- 2011-06-24 KR KR1020127034087A patent/KR101834024B1/ko active Active
-
2012
- 2012-12-19 MX MX2016001250A patent/MX346901B/es unknown
-
2015
- 2015-03-25 US US14/668,683 patent/US9358297B2/en active Active
-
2021
- 2021-11-03 CY CY20211100950T patent/CY1124690T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535422A5 (https=) | ||
| JP6008849B2 (ja) | 置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤 | |
| EP3501498B1 (en) | Composition and methods of treatment | |
| JP6738376B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| US9144568B1 (en) | Formulations of bendamustine | |
| EP3468544A2 (en) | Synergistic antifungal compositions and methods thereof | |
| WO2017216722A2 (en) | Synergistic antifungal compositions and methods thereof | |
| BR112016030541B1 (pt) | Uso de um esteróide antimicrobiano catiônico (csa) para a preparação de um medicamento para o tratamento de uma infecção fúngica | |
| JP2014510067A5 (https=) | ||
| US12521406B2 (en) | Use of compounds in the treatment of fungal infections | |
| ES2390472T3 (es) | Combinación farmacéutica que comprende un agente antifúngico y un principio activo que es especialmente eugenol o carvacrol | |
| US20200338082A1 (en) | Formulations, systems, and methods for therapeutic treatment | |
| AU2013377404B2 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| AU2011273064A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| WO2012001494A2 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| KR20230024375A (ko) | 진균 감염을 치료하기 위한 화합물 및 방법 | |
| RU2805930C1 (ru) | Использование соединений при лечении грибковых инфекций | |
| US20180193335A1 (en) | Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors | |
| TH128834A (th) | วิธีการสำหรับการใช้วาโซเพรสซินแอนทาโกนิสต์กับตัวกระทำเคมีบำบัดแอนธราไซคลีนเพื่อลดสภาพเป็นพิษต่อหัวใจ และ/หรือการปรับปรุงการรอดชีวิต |